Of the 617 patients enrolled in the KEYNOTE-826 trial (446 squamous cell carcinoma, 140 adenocarcinoma, 29 adenosquamous carcinoma, and 2 other), the PD-L1-positive (CPS≥1) rate was 88.8% [31]. Zong et al. presented the rates of PD-L1 positivity by histological type of uterine cervical cancer and reported that 91% (91/100) of squamous cell carcinomas were PD-L1-positive, compared with 22% (11/50) of clear cell carcinomas [32]. Meanwhile, in this case, the patient with CPS≥1 was expected to respond to pembrolizumab, so she was administered TC+bevacizumab+pembrolizumab therapy. Here, CD274 is linked to adenocarcinoma.